| Welcome to FierceLifeSci Weekly Digest, your roundup of the biggest and most popular stories from each of our publications. | |
|
Featured Story | | | Monday, November 27, 2017 New Teva CEO Kare Schultz is getting down to business—and quickly. Monday, the troubled Israeli drugmaker unveiled a new structure and changes to its leadership team, and it promised its restructuring plan would arrive earlier than expected, too. The company will put its generics and specialty products together under one commercial roof, with segments in North America, Europe and Growth Markets. |
|
|
Top Stories Of The Week Wednesday, November 22, 2017 A team of ex-Takeda scientists has struck out on its own with cancer assets licensed from the drugmaker. The resulting biotech, Chordia Therapeutics, starts life with multiple oncology drugs, lab space at a Takeda site and funding from the Japanese firm and a VC syndicate. Monday, November 20, 2017 Pharma stands to prevail again in Washington, D.C., if a new Part D rule proposal from the Centers for Medicare & Medicaid Services comes to fruition. Last week, the agency put out potential changes to solicit feedback, with a drug pricing tweak one area under consideration. Monday, November 20, 2017 Bayer has signed a new and potentially major research pact with Japan’s PeptiDream, marking the second big biobucks deal of its kind for the German pharma in the past week. Monday, November 20, 2017 Two of Roche's new generation of drugs—including the just-approved hemophilia therapy Hemlibra—racked up new data Monday that bolster their case for blockbuster sales. That's good for the drugmaker, whose top-selling cancer meds are facing a growing threat from biosimilars. Wednesday, November 22, 2017 Eli Lilly has unveiled its device-driven strategy for weathering the competitive and pricing pressures faced by its diabetes unit. The Big Pharma is working on insulin delivery devices that move it onto Medtronic’s turf and has teamed up with Dexcom to add continuous glucose monitoring systems to its arsenal. Wednesday, November 29, 2017 After an analysis showed that Sanofi's highly touted dengue vaccine could lead to more serious infections if used in the wrong setting, the company is requesting a label change that will likely lead to fewer eligible recipients. With the development, Sanofi is taking a €100 million ($119 million) charge in the fourth quarter. Tuesday, November 21, 2017 Scientists at the International AIDS Vaccine Initiative and the Scripps Research Institute have identified viral changes and antibody features that could provide a possible template for HIV vaccine design that tackles the virus's diversity and evasiveness. Monday, November 27, 2017 With plans for a major expansion of its North Carolina site, Fresenius Kabi's investments aimed primarily at the U.S. generics market now top $5 billion as the German drugmaker bets on growth in sterile injectables. Thursday, November 30, 2017 Gilead Sciences has teamed up with privately held X-Chem, which will screen its DNA-encoded libraries containing over 120 billion small molecules, in the hope of finding new drugs in antiviral and other therapeutic areas. Resources Sponsored by: Deloitte Sourcing research externally seems to be the preferred path for biopharma companies to strengthen their R&D pipeline. Sponsored by: Veeva Systems Read this guide if you’re a global life sciences company - conducting clinical trials across several countries, or manufacturing and distributing products in multiple regions - to learn five steps to align and improve quality oversight, as well as avoid common mistakes in harmonization initiatives. Sponsored by: Veeva Systems Read Deloitte Consulting's whitepaper on the value of a holistic RIM capability, covering the potential cost savings and revenue gains from doing RIM right. Sponsored by: Veeva Systems See the results from one of the largest, most in-depth surveys of clinical data management professionals on data management practices, performance, and challenges. Sponsored by: Veeva Systems Gain a complete, real-time view of quality and streamline operations. Incorporate partners into processes for critical oversight and 30% greater efficiency, and transform cross-functional processes like change control. Presented by: DSM Biomedical Discover DSM's Dyneema Purity® membrane, an effective and efficient material to construct stent grafts used in minimally invasive surgeries to treat both cardiovascular and peripheral arterial diseases. Sponsored by: ePharmaSolutions As clinical trials become more complex, safety document distribution to investigative sites has reached the point that demands a solution. Sponsored by: Ashfield Healthcare December 5, 2017 | 2pm EST / 11am PST Join this webinar to learn methods that maintain and build sales momentum despite turnover. Sponsored by: Veeva CROs are leading an industry wide shift to modernize clinical systems and clinical trial processes. | 
